Research Groups and R&D Platforms: Basic research
The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.
High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
3D oncology models, phenotypic screens, high-content screens:
Medicinal chemistry, virtual screening and molecular modelling:
Assay development, Basic research, Disease models, High throughput imaging, Hit to lead, Lead optimization, Medicinal chemistry, Molecular modelling, R&D Platforms, Screening, Signaling, Target discovery
Cytoskeletal and survival signaling
Turku Centre for Biotechnology &
Cell Biology, Faculty of Science and Engineering,
Åbo Akademi University
Atomic-force microscopy, Basic research, Biochemistry, Cancer, Diabetes, Diagnostics, Electron microscopy, High throughput imaging, Imaging, In Vitro Diagnostics, Metabolic diseases, Molecular Biology, Molecular Cell Biology, Nanoparticles, Natural Compounds, Natural products, Physiology, Proteomics, Receptor, Signaling, Super-resolution imaging, Target discovery
The Turku Metabolomics Centre
The Turku Metabolomics Centre (TMC) was established in the Fall of 2017, and currently comprises four analytical laboratories on the University of Turku and Åbo Academy campuses, with the primary focus on biomedical and clinical applications. TMC covers a broad range of analytical methods, useful for discovery studies, hypothesis-driven targeted studies as well as clinical applications in Good Laboratory Practice (GLP) setting. The methods include:
1. Targeted quantitative analyses by mass spectrometry (MS) of specific groups of metabolites, e.g. bile acids, endocannabinoids, amino acids, eicosanoids.
2. Global profiling of molecular lipids (lipidomics) and polar metabolites.
3. Diagnostic, drug metabolism and pharmacokinetic applications in Good Laboratory Practice (GLP) setting.
4. Tissue metabolomics by Nuclear Magnetic Resonance (NMR).
5. How dietary intake affects blood metabolism.
TMC infrastructure currently includes 7 MS instruments (2 x UHPLC-QTRAP/QqQ-MS, 2 x UHPLC-QqQ-MS, 1 x GC-QqQ-MS, 2 x GC-QMS) and 2 NMR instruments (1 x 600 MHz and 1 x 400 MHz). The 400 MHz spectrometer is equipped with a high resolution magic angle spinning probe for the detection of metabolites in tissue and cell samples without the need for extensive sample preparation. The 600MHz instrument is equipped with a cooled sample handling robot with space for 300 samples allowing high throughput liquid NMR studies. Two new MS instruments also being purchased this year.
Basic research, Bioinformatics, Diagnostics, In Vitro Diagnostics, Machine learning, Metabolomics, NMR, Pattern recognition, R&D Platforms, Systems Biology, Target discovery
Turku BioImaging, TBI (www.bioimaging.fi), is an umbrella organization for “all things imaging” in Turku, jointly operated by Åbo Akademi University and the University of Turku. TBI was initiated in 2007 as a broad-based, interdisciplinary imaging consortium that aims at bringing together all biological and medical imaging expertise in Turku and elsewhere in Finland. In 2017, Turku BioImaging is celebrating its journey of 10 years, from a small 2-person unit to a large, fully functioning organization.
Atomic-force microscopy, Basic research, Clinical development, Diagnostics, Electron microscopy, FTIR or RAMAN microscopy, High throughput imaging, Imaging, Imaging software, In Vivo Diagnostics, PET, Preclinical development, R&D Platforms, Super-resolution imaging, Ultrasound imaging
Molecular mechanisms of diseases
Institute of Biomedicine,
University of Turku
Basic research, Bioinformatics, Biomedicine, Biomolecular chemistry, Cancer, Cardiovascular diseases, Developmental disorders, Medicinal chemistry, Molecular modelling, NMR, Structural Biology, Target discovery, X-ray crystallography
Department of Chemistry,
University of Turku
Basic research, Biomolecular chemistry, Diagnostics, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Lead optimization, NMR, Nucleic acids, Organic Chemistry, Organic compounds, Synthetic chemistry